Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1987 Oct;84(20):7257–7260. doi: 10.1073/pnas.84.20.7257

Pancreastatin and islet hormone release.

S Efendić 1, K Tatemoto 1, V Mutt 1, C Quan 1, D Chang 1, C G Ostenson 1
PMCID: PMC299271  PMID: 2890162

Abstract

The effect of pancreastatin on the release of insulin, glucagon, and somatostatin was studied in the isolated perfused rat pancreas. After an initial equilibration period (-20 to 0 min) with a basal glucose concentration (3.3 mM), the pancreata were perfused with either 16.7 mM glucose (0-40 min) or with 20 mM arginine (0-20 min). Pancreastatin was introduced 10 min prior to and throughout the administration of the high glucose and arginine and continued during their perfusion. As expected, the glucose and the arginine augmented insulin and somatostatin release. Pancreastatin (1 and 10 nM) markedly suppressed the first phase of insulin release with both insulinogogues used, while the early somatostatin secretion was not significantly decreased. However, the peak incremental somatostatin response to arginine was reduced by 50% (P less than 0.05). Conversely, the peptide (10 nM) tended to augment arginine-induced glucagon release. Pancreastatin (100 nM) also suppressed glucose-stimulated insulin release from isolated rat islets. These pancreastatin-mediated alterations in islet hormone release are reminiscent of those known to characterize non-insulin-dependent diabetes. Therefore, the significance of pancreastatin in islet physiology and pathophysiology deserves special consideration.

Full text

PDF
7257

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aguilar-Parada E., Eisentraut A. M., Unger R. H. Pancreatic glucagon secretion in normal and diabetic subjects. Am J Med Sci. 1969 Jun;257(6):415–419. doi: 10.1097/00000441-196906000-00008. [DOI] [PubMed] [Google Scholar]
  2. Dunning B. E., Ahren B., Veith R. C., Böttcher G., Sundler F., Taborsky G. J., Jr Galanin: a novel pancreatic neuropeptide. Am J Physiol. 1986 Jul;251(1 Pt 1):E127–E133. doi: 10.1152/ajpendo.1986.251.1.E127. [DOI] [PubMed] [Google Scholar]
  3. Efendić S., Luft R., Wajngot A. Aspects of the pathogenesis of type 2 diabetes. Endocr Rev. 1984 Summer;5(3):395–410. doi: 10.1210/edrv-5-3-395. [DOI] [PubMed] [Google Scholar]
  4. Efendić S., Nylén A., Roovete A., Uvnäs-Wallenstein K. Effects of glucose and arginine on the release of immunoreactive somatostatin from the isolated perfused rat pancreas. FEBS Lett. 1978 Aug 1;92(1):33–35. doi: 10.1016/0014-5793(78)80715-7. [DOI] [PubMed] [Google Scholar]
  5. Eiden L. E. Is chromogranin a prohormone? Nature. 1987 Jan 22;325(6102):301–301. doi: 10.1038/325301a0. [DOI] [PubMed] [Google Scholar]
  6. Grube D., Aunis D., Bader F., Cetin Y., Jörns A., Yoshie S. Chromogranin A (CGA) in the gastro-entero-pancreatic (GEP) endocrine system. I. CGA in the mammalian endocrine pancreas. Histochemistry. 1986;85(6):441–452. doi: 10.1007/BF00508425. [DOI] [PubMed] [Google Scholar]
  7. Gutniak M., Grill V., Efendić S. Effects of insulin on fasting and meal-stimulated somatostatin-like immunoreactivity in noninsulin-dependent diabetes mellitus: evidence for more than one mechanism of action. J Clin Endocrinol Metab. 1986 Jan;62(1):77–83. doi: 10.1210/jcem-62-1-77. [DOI] [PubMed] [Google Scholar]
  8. HALES C. N., RANDLE P. J. Immunoassay of insulin with insulin-antibody precipitate. Biochem J. 1963 Jul;88:137–146. doi: 10.1042/bj0880137. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Huttner W. B., Benedum U. M. Chromogranin A and pancreastatin. Nature. 1987 Jan 22;325(6102):305–305. doi: 10.1038/325305b0. [DOI] [PubMed] [Google Scholar]
  10. Kaiser E., Colescott R. L., Bossinger C. D., Cook P. I. Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides. Anal Biochem. 1970 Apr;34(2):595–598. doi: 10.1016/0003-2697(70)90146-6. [DOI] [PubMed] [Google Scholar]
  11. Loubatières A., Mariani M. M., Chapal J. Insulino-sécrétion étudiée sur le pancréas isolé et perfusé du rat. I. Synergie entre glucose et sulfamides hypoglycémiants. Diabetologia. 1970 Oct;6(5):457–466. doi: 10.1007/BF01211884. [DOI] [PubMed] [Google Scholar]
  12. Matsueda G. R., Stewart J. M. A p-methylbenzhydrylamine resin for improved solid-phase synthesis of peptide amides. Peptides. 1981 Spring;2(1):45–50. doi: 10.1016/s0196-9781(81)80010-1. [DOI] [PubMed] [Google Scholar]
  13. McDonald T. J., Dupre J., Tatemoto K., Greenberg G. R., Radziuk J., Mutt V. Galanin inhibits insulin secretion and induces hyperglycemia in dogs. Diabetes. 1985 Feb;34(2):192–196. doi: 10.2337/diab.34.2.192. [DOI] [PubMed] [Google Scholar]
  14. O'Connor D. T. Chromogranin: widespread immunoreactivity in polypeptide hormone producing tissues and in serum. Regul Pept. 1983 Jul;6(3):263–280. doi: 10.1016/0167-0115(83)90145-3. [DOI] [PubMed] [Google Scholar]
  15. Rindi G., Buffa R., Sessa F., Tortora O., Solcia E. Chromogranin A, B and C immunoreactivities of mammalian endocrine cells. Distribution, distinction from costored hormones/prohormones and relationship with the argyrophil component of secretory granules. Histochemistry. 1986;85(1):19–28. doi: 10.1007/BF00508649. [DOI] [PubMed] [Google Scholar]
  16. Szecówka J., Tendler D., Efendić S. Effects of PHI on hormonal secretion from perfused rat pancreas. Am J Physiol. 1983 Oct;245(4):E313–E317. doi: 10.1152/ajpendo.1983.245.4.E313. [DOI] [PubMed] [Google Scholar]
  17. Tatemoto K., Carlquist M., Mutt V. Neuropeptide Y--a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide. Nature. 1982 Apr 15;296(5858):659–660. doi: 10.1038/296659a0. [DOI] [PubMed] [Google Scholar]
  18. Tatemoto K., Efendić S., Mutt V., Makk G., Feistner G. J., Barchas J. D. Pancreastatin, a novel pancreatic peptide that inhibits insulin secretion. Nature. 1986 Dec 4;324(6096):476–478. doi: 10.1038/324476a0. [DOI] [PubMed] [Google Scholar]
  19. Tatemoto K. Isolation and characterization of peptide YY (PYY), a candidate gut hormone that inhibits pancreatic exocrine secretion. Proc Natl Acad Sci U S A. 1982 Apr;79(8):2514–2518. doi: 10.1073/pnas.79.8.2514. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Tatemoto K., Lundberg J. M., Jörnvall H., Mutt V. Neuropeptide K: isolation, structure and biological activities of a novel brain tachykinin. Biochem Biophys Res Commun. 1985 Apr 30;128(2):947–953. doi: 10.1016/0006-291x(85)90138-x. [DOI] [PubMed] [Google Scholar]
  21. Tatemoto K., Mutt V. Chemical determination of polypeptide hormones. Proc Natl Acad Sci U S A. 1978 Sep;75(9):4115–4119. doi: 10.1073/pnas.75.9.4115. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Tatemoto K., Mutt V. Isolation and characterization of the intestinal peptide porcine PHI (PHI-27), a new member of the glucagon--secretin family. Proc Natl Acad Sci U S A. 1981 Nov;78(11):6603–6607. doi: 10.1073/pnas.78.11.6603. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Tatemoto K., Rökaeus A., Jörnvall H., McDonald T. J., Mutt V. Galanin - a novel biologically active peptide from porcine intestine. FEBS Lett. 1983 Nov 28;164(1):124–128. doi: 10.1016/0014-5793(83)80033-7. [DOI] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES